Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
350 participants
OBSERVATIONAL
2023-11-01
2024-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In advanced/metastatic disease, treatments follow the standards for urothelial carcinoma including platinum-based chemotherapy and anti-PD(L)1 (Programmed death (ligand) 1) immunotherapy, with no regard as to the primary disease site (bladder or upper tract). Given the rarity of UTUC, efficacy data in the UTUC subgroup of advanced urothelial carcinoma is scarce.
UTUC show distinct pahological and molecular features, including higher prevalence of microsatellite instability and of abnormalities in the FGFR (fibroblast growth factor receptors) gene family. These specific features may impact outcomes of immunotherapy in advanced/metastatic UTUC.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
NCT06120374
Antitumor T Cell Responses in Patients With Bladder Cancer
NCT06334406
Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based Chemotherapy in Locally Advanced Upper Tract Urothelial Carcinoma
NCT04672317
Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy
NCT03387761
Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma
NCT05160285
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with advanced/metastatic UTUC treated with second-line anti-PD-(L)1 immunotherapy
Evaluation of anti-PD-(L)1 immunotherapy efficacy
Non Applicable, research on data
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Evaluation of anti-PD-(L)1 immunotherapy efficacy
Non Applicable, research on data
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of urothelial carcinoma (with or without variant histology)
* Advanced/metastatic disease not amenable to local treatment with curative intent
* Treatment with an anti-PD-(L)1 monoclonal antibody initiated between 2016 and 2022
Exclusion Criteria
* Urothelial carcinoma of bladder or urethral primary site
* Non-urothelial tumor
* Maintenance immunotherapy initiated without disease progression
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP230738
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.